What is Juniper Genomics?
Juniper Genomics is a pioneering biotechnology firm dedicated to transforming the landscape of IVF care. By utilizing the world's first embryo screening test that integrates whole genome and transcriptome sequencing, the company provides a comprehensive diagnostic tool that avoids the limitations of conventional polygenic risk scores. Founded by a multidisciplinary team of experts in genomics, reproductive medicine, and bioethics, Juniper Genomics is establishing a new standard for embryo health assessment. Their platform analyzes millions of genetic markers to offer actionable insights, effectively bridging the gap between complex genomic data and clinical decision-making in fertility clinics.
How much funding has Juniper Genomics raised?
Juniper Genomics has raised a total of $4.6M across 1 funding round:
Seed
$4.6M
Seed (2025): $4.6M with participation from Blue Collective, MBX Capital, Innospark Ventures, and Amboy Street Ventures
Key Investors in Juniper Genomics
Blue Collective
Blue Collective is a venture capital and private equity firm that invests in exceptional individuals who are building remarkable businesses through a people-first and values-driven approach.
MBX Capital
MBX Capital is a boutique venture capital firm that partners with and creates healthcare and biotechnology companies that are disrupting conventions in service to public health.
Innospark Ventures
Innospark Ventures is an investment firm that supports founders addressing complex challenges through Artificial Intelligence, focusing on applied AI in sectors such as healthcare and life sciences.
What's next for Juniper Genomics?
With this major enterprise-level funding, Juniper Genomics is well-positioned to transition from its initial development phase into a period of rapid commercial expansion. The strategic roadmap likely includes scaling laboratory infrastructure to meet increasing demand and expanding clinical partnerships to integrate their screening technology into standard IVF protocols. Furthermore, the company is expected to continue its research initiatives, potentially exploring new applications for its sequencing platform within the broader reproductive health market. By maintaining a rigorous ethical framework while pushing the boundaries of genetic science, Juniper Genomics is poised to capture significant market share in the multi-billion dollar fertility industry.
See full Juniper Genomics company page
